Sie sind auf Seite 1von 2

1. Friedman S, Blumberg RS. Inflammatory Bowel Disease. In: Longo DL, Fauci AS, Editors.

Harrison’s Gastroenterology and Hepatology. 17th edition. United states: The McGraw-
Hill Companies; 2010;16:174-95.
2. Perkumpulan Gastroenterologi Indonesia (PGI). Konsensus Nasional Tatalaksana
Inflammatory Bowel Disease (IBD). 2015
3. Olendzki BC, Silverstain TD, Persuitte GM, Ma Y, Baldwin KR, Cave D. An anti-
inflammatory diet as treatment for inflammatory bowel disease: a case series report. Nutrition
J.2014;13:5.
4. FAO/WHO. Health and Nutritional Properties of Probiotics in Food including Powder Milk
with Live Lactic Acid Bacteria. [internet] 2001 [citied 2016 Apr 4] Available from:
ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf.
5. Mattu B, Chauhan A. Lactic acid bacteria and its use in Probiotics. Journal of Bioremediation
& Biodegradation. 2013: 4; e140:8.
6. Kelly D, Conway S, Aminov R. Commensal gut bacteria: mechanisms of immune
modulation. Trends in Immunology. 2005: 26: 326–333.
7. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human Intestinal Lumen and Mucosa-Associated
Microbiota in Patients with Colorectal Cancer. PLoS ONE 2012: 7(6); e39743.
8. Prideaux L, Kamm MA, Cruz PP, Chan FK, Ng SC. Inflammatory Bowel Disease in
Asia. J Gastroenterol Hepatol. 2012 Aug; 27(8):1266-80.
9. Ringel Y, Quigley MM, Lin HC. Using Probiotics in Gastrointestinal Disorders. Am J
Gastroenterol Suppl. 2012; 1:34– 40.
10. Faujan NH, Abdulamir AS, Fatimah AB, Anas M, Shuhaimi M, Yazid AM, et al. The Impact
of the Level of the Intestinal Short Chain Fatty Acids in Inflammatory Bowel Disease Patients
Versus Healthy Subjects. Open Biochem J. 2010 May; 4:53-8.
11. Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, et al. Imbalance
in intestinal microflora constitution could be involved in the pathogenesis of
inflammatory bowel disease. Int. J. Med. Microbiol. 2008;298: 463–72
12. Vernia P, Gnaedinger A, Hauck W, Breuer R.I. Organic anions and the diarrhea of
inflammatory bowel disease. Dig. Dis. Sci. 1988; 33: 1353–58.

13. Ishikawa H, Matsumoto S, Ohashi Y. Imaoka A. Setoyama H, Umesaki Y. Beneficial


effects of probiotic Bifidobacterium and galacto-oligosaccharide in patients with
ulcerative colitis: a randomized controlled study. Digestion. 2011: 84; (2): 128–33.

14. Soleimani A, Mojarrad M.Z, Bahmani F, Taghizadeh M, Ramezani M, Ebrahimi M.T,


et. Al. Probiotic supplementation in diabetic hemodialysis patients has beneficial
metabolic effects. J Kint. 2016; 10: 1016.
15. Geirnaert A, Wang J, Tinck M, Steayert A, Abbeele P.V, Eekhaut V, et al.
Interindividual differences in response to treatment with butyrate-producing
Butyricicoccus pullicaecorum 25–3T studied in an in vitro gut model. FEMS Microbiol
Ecology. March: 2015; 91(6):1-12.

16. Tursi A, Brandimarte G, Papa A. Treatment of relapsing mild-to-moderate ulcerative


colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a
doubleblind, randomized, placebo-controlled study. Am J Gastroenterol. 2010: 105(10):
2218-27.
17. Sood A, Midha V, Makharia G. K, et al. The probiotic preparation, VSL#3 induces
remission in patients with mild-to-moderately active ulcerative colitis. Clin
Gastroenterol Hepatol. 2009;7(11):1202–09.